Sophiris bio inc. (SPHS)
CashFlow / TTM
Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Cash flows used in operating activities
Net loss

37

-1,876

-5,809

-6,778

-16,262

-16,044

-9,338

-8,628

-5,211

-6,840

-11,541

-11,164

-13,116

-12,488

-12,135

-14,197

-16,976

-21,546

-26,556

-30,712

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation

787

853

854

860

1,061

1,266

1,541

1,712

1,487

1,107

737

425

405

507

639

776

990

1,392

1,709

2,091

0

0

0

Accretion of debt discount

137

144

147

149

150

119

81

44

7

19

49

81

114

130

135

137

137

134

154

188

0

0

0

Amortization of promissory note issuance costs

52

53

56

56

57

46

31

17

0

0

0

-

-

-

-

-

-

-

-

38

0

0

0

Depreciation and amortization

0

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation of property and equipment

-

-

-

-

-

-

-

4

4

6

9

12

17

19

20

20

20

20

31

47

0

0

0

Amortization of premium/discount on securities available-for-sale

34

32

39

51

47

11

-48

-116

-139

-112

-67

-20

-2

-4

-3

-5

-8

-10

-24

-39

0

0

0

Change in fair value warrant liability

-10,652

-9,524

-7,887

-8,690

455

-63

-4,749

-3,307

-5,544

-4,523

416

330

0

0

0

-

-

-

-

-49

0

0

0

Foreign exchange transaction loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-6

-33

-10

0

-1

0

0

0

Other

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-6

-3

0

0

0

Other receivables

-

-

-

-

-

-

-

-

-

-

86

-

-6

-6

-16

-8

-1

-9

-38

-33

0

0

0

Prepaid expenses and other current assets

-177

-749

-598

-373

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-2,076

-2,358

-1,596

-716

-1,354

-734

0

0

0

Accounts payable

-63

-714

-338

963

-313

769

773

374

459

302

-32

-446

-516

-565

-1,148

-1,728

-3,114

-2,895

-2,870

1,171

0

0

0

Accrued expenses

-1,352

-1,508

-664

-349

608

1,501

1,054

-269

-90

480

145

1,195

327

-988

-840

-1,742

-1,659

-131

373

186

0

0

0

Operating lease liability

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-10,543

-11,844

-13,073

-13,457

-13,991

-12,448

-10,526

-9,968

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-11,244

-

-18,964

-22,281

-25,740

-26,230

0

0

0

Cash flows (used in) provided by investing activities
Purchases of property and equipment

-

-

-

4

4

5

5

3

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Maturities of securities available-for-sale

5,100

6,150

7,437

11,887

18,812

25,157

24,911

22,161

12,736

4,291

2,600

2,750

7,250

10,550

16,549

26,169

26,569

31,169

39,871

43,201

0

0

0

Purchases of securities available-for-sale

4,617

2,573

2,969

3,616

9,233

12,516

13,918

15,835

24,701

21,621

19,229

16,471

2,504

5,329

7,755

10,103

18,561

22,029

27,300

28,501

0

0

0

Net cash (used in) provided by investing activities

483

3,576

4,466

8,267

9,575

12,636

10,988

6,323

-11,968

-17,331

-16,629

-13,721

4,746

5,221

8,794

16,066

8,006

9,134

12,562

14,691

0

0

0

Cash flows provided by financing activities
Proceeds from exercise of stock options

-

-

-

-

-

-

-

2

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Payment of offering costs related to the establishment of the Controlled Equity Sales Agreement

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

53

0

0

0

Principal payments on note payable

-

-

-

-

-

-

-

-

-

-

-

5,141

5,585

1,656

1,190

735

291

0

1,700

3,361

0

0

0

Net cash provided by financing activities

0

0

0

-

-

-

-

6,932

6,824

26,281

31,428

30,971

31,443

4,742

-405

50

-291

-93

2,553

839

0

0

0

Effect of exchange rate changes on cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-2

12

8

7

-1

-17

-21

-13

-16

0

0

0

Net decrease in cash and cash equivalents

-7,797

-8,969

-8,608

-5,089

-4,438

7,117

7,392

3,287

-14,569

-1,514

3,748

6,919

26,147

344

-2,848

1,758

-11,266

-13,261

-10,638

-10,716

0

0

0

Valuation of exercised warrants reclassified from warrant liability to contributed surplus

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

Change in the fair value of stock-based compensation liability recorded to contributed surplus

-

-

-

-

-

-

-

-57

-195

-102

-98

-111

153

49

88

146

-233

-267

-149

-180

0

0

0